Clinical medicine

Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'

Monday, November 30, 2020 - 7:23am

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Nordic Nanovector announces change of its Oslo Børs ticker symbol to 'NANOV'

Monday, November 30, 2020 - 7:20am

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.

Key Points: 
  • Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care.
  • The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
  • Nordic Nanovector's lead clinical-stage candidate is Betalutin, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
  • Nordic Nanovector retains global marketing rights to Betalutin and intends to actively participate in the commercialisation of Betalutin in the US and other major markets.

Dupixent® (dupilumab) approved by European Commission as first and only biologic medicine for children aged 6 to 11 years with severe atopic dermatitis

Monday, November 30, 2020 - 6:00am

Young children with severe atopic dermatitis currently have few treatment choices and significant unmet needs.We welcome the addition of new medicines for these underserved patients."

Key Points: 
  • Young children with severe atopic dermatitis currently have few treatment choices and significant unmet needs.We welcome the addition of new medicines for these underserved patients."
  • In addition, uncontrolled severe atopic dermatitis can have a substantial emotional and psychosocial impact, causing sleep disturbance, symptoms of anxiety and depression and feelings of isolation in children.
  • Dupixents ability to providesignificantly clearer skin, and clinically meaningful reduction of persistent itch, addresses important unmet needs for these children.
  • In addition to atopic dermatitis, we continue to investigate the potential of Dupixent in younger age groups and across a variety of type 2 inflammatory diseases.

Rheumatoid arthritis patients take to Reddit for mental health support

Friday, November 27, 2020 - 11:10pm

VANCOUVER, BC, Nov. 27, 2020 /CNW/ -According to a new Arthritis Research Canada study, rheumatoid arthritis patients are turning to Reddit a popular social media platform to discuss their mental health.

Key Points: 
  • VANCOUVER, BC, Nov. 27, 2020 /CNW/ -According to a new Arthritis Research Canada study, rheumatoid arthritis patients are turning to Reddit a popular social media platform to discuss their mental health.
  • They discovered people with rheumatoid arthritis (RA) are using Reddit to talk about how managing their disease affects their mental health, relationships and social isolation, feelings of loss and emotional struggles.
  • Internet-based communities and online forums where patients discuss mental health experiences, seek advice, and receive peer-to-peer support may represent an authentic source of data for informing questions about the impacts of RA on mental health.
  • Arthritis Research Canada is leading research aimed at arthritis prevention, early diagnosis, new and better treatment, and improved quality of life.

Hong Kong Wound Dressing Market Report 2020-2030 - ResearchAndMarkets.com

Friday, November 27, 2020 - 5:01pm

The "Hong Kong Wound Dressing Market Research Report: By Type, Application, End User, Distribution Channel - Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hong Kong Wound Dressing Market Research Report: By Type, Application, End User, Distribution Channel - Industry Analysis and Growth Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The Hong Kong wound care market is predicted to reach a value of $80.7 million by 2030, rising from $46.0 million in 2019, progressing at a 5.4% CAGR during the forecast period (2020-2030).
  • In terms of application, the Hong Kong wound care market is categorized into acute wounds and chronic wounds, between which, the chronic wound category held the major share of the market in 2019.
  • The rapidly increasing prevalence of diabetes is also a major factor resulting in the growth of the Hong Kong wound care market.

India Glucose Monitoring Devices Market Competition, Forecast & Opportunities, 2026: Self-Monitoring Glucose Devices and Continuous Glucose Monitoring Devices - ResearchAndMarkets.com

Friday, November 27, 2020 - 3:38pm

The "India Glucose Monitoring Devices Market, By Product (Self-Monitoring Glucose Devices and Continuous Glucose Monitoring Devices), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By End User, By Region, Competition, Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "India Glucose Monitoring Devices Market, By Product (Self-Monitoring Glucose Devices and Continuous Glucose Monitoring Devices), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), By End User, By Region, Competition, Forecast & Opportunities, FY 2026" report has been added to ResearchAndMarkets.com's offering.
  • The Indian Glucose Monitoring Devices Market was valued at around USD 209 million in FY2020 and is forecast to grow at a CAGR of more than 10% until FY 2026.
  • The Indian Glucose Monitoring Devices Market is driven by growing prevalence of diabetes in the country, predominantly Type 2 diabetes.
  • The Indian Glucose Monitoring Devices Market is segmented based on product, application, end-user, and region.

Transpara® breast AI by ScreenPoint Medical reaches major milestone in the lead up to Radiological Society of North America 2020

Friday, November 27, 2020 - 3:00pm

Transpara led the way being the first to use a unique scoring breast AI system for breast cancer risk.

Key Points: 
  • Transpara led the way being the first to use a unique scoring breast AI system for breast cancer risk.
  • "This is a major milestone in our mission to help radiologists improve survival rates for breast cancer, a disease that is growing relentlessly around the world," said Nico Karssemeijer, CEO for ScreenPoint Medical.
  • "Despite the challenges presented by COVID in 2020, Transpara installations continue to prove successful in more and more countries."
  • "AI is obviously an important weapon being adopted to fight breast cancer even during these trying times.

Global $525+ Million Typhoid Fever Vaccines Markets, 2019-2020 & 2027 - ResearchAndMarkets.com

Friday, November 27, 2020 - 2:40pm

The "Typhoid Fever Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Vaccine Type; Route of administration, and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Typhoid Fever Vaccines Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Vaccine Type; Route of administration, and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The market is expected to reach US$ 525.32 million by 2027 from US$ 262.81 million in 2019 and is estimated to grow with a CAGR of 9.3% from 2020 to 2027.
  • The Live Attenuated Vaccine segment is likely to register highest CAGR in the global Typhoid fever vaccines market during the forecast period.
  • Global Typhoid fever vaccines Market, based on route of administration, the Typhoid fever vaccines market is segmented into oral and injections.

Global Inhaled and Intranasal Products 2020-2030: Contract Service Providers Market - Focus on Drugs and Drug Delivery Systems - ResearchAndMarkets.com

Friday, November 27, 2020 - 2:24pm

The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Inhaled and Intranasal Products Contract Service Providers Market, 2020-2030" report has been added to ResearchAndMarkets.com's offering.
  • The 'Inhaled and Intranasal Products: Contract Service Providers Market (Focus on Drugs and Drug Delivery Systems), 2020 - 2030' report features an extensive study of the current market landscape and future opportunities for the contract service providers focused on drugs and drug delivery systems.
  • It features an in-depth analysis, highlighting the capabilities of various contract service providers engaged in this domain.
  • Who are the leading contract service providers offering inhalable and intranasal products related services, across the world?

Diabetes Drug Delivery Devices Market, 2030 - ResearchAndMarkets.com

Friday, November 27, 2020 - 2:02pm

The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade.

Key Points: 
  • The "Diabetes Drug Delivery Devices Market, 2020-2030" report features an extensive study of the current market landscape and the likely adoption of diabetes drug delivery devices, over the next decade.
  • One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for diabetes drug delivery devices.
  • An overview of the current market landscape of diabetes drug delivery devices available for delivery of insulin and non-insulin drugs, including information on device specifications, such as type of device (insulin pump, pen-injector/autoinjector, jet injector, microneedle patch, nasal delivery system, insulin port, oral delivery system and inhalation device), stage of development (marketed, clinical and preclinical), route of administration (subcutaneous, intramuscular, transdermal, oral, intranasal and others), mode of drug delivery (invasive, minimally invasive and non-invasive), needle attributes (needleless, detachable needle, cannula, hidden needle and fixed needle), type of drug delivery system (mechanical method and electrical method), drug administration speed (fast and slow), device usability (disposable, reusable and reusable (disposable components)), diabetes type (type I diabetes, type II diabetes and diabetes type (unspecified)) and type of drug (insulin and non-insulin).
  • A detailed competitiveness analysis of diabetes drug delivery devices based on various relevant parameters, such as supplier power (based on the experience/expertise of the developer) and product specifications (type of device, route of administration, diabetes type, needle attributes, availability of needle safety system, self-administration potential, mode of drug delivery, device usability, drug administration speed and development stage).